Angelika von Wallbrunn, Jens Waldeck, Carsten Hoeltke, Michael Zühlsdorf, Rolf Mesters, Walter Heindel M.D., Michael Schäfers, Christoph Bremer
Journal of Biomedical Optics, Vol. 13, Issue 01, 011007, (January 2008) https://doi.org/10.1117/1.2839046
TOPICS: Tumors, Luminescence, In vivo imaging, Optical imaging, Tissues, Tomography, Reflectivity, Proteins, Imaging systems, Tissue optics
The metalloexopeptidase CD13/aminopeptidase N (APN) has been shown to be involved in cancer angiogenesis, invasion, and metastasis. Therefore, a CD13/APN–targeted NGR-peptide was labeled with the cyanine dye Cy 5.5 and applied to image tumor xenografts with different APN-expression levels using both planar and tomographic optical imaging methods. In vitro, the peptide-dye conjugate showed a clear binding affinity to APN-positive HT-1080 cells, while negative MCF-7 cells and predosing with the free NGR-peptide revealed little to no fluorescence. In vivo, tumor xenografts (n≥5) were clearly visualized by two-dimensional (2-D) planar fluorescence reflectance imaging (FRI) and three-dimensional (3-D) fluorescence mediated tomography (FMT) up to 24 h after injection. FMT also allowed us to quantify fluorochrome distribution in deeper tissue sections, showing an average fluorochrome concentration of 306.7±54.3 nM Cy 5.5 (HT-1080) and 116.0±18.3 nM Cy 5.5 (MCF-7) in the target tissue after 5 h. Competition with the free NGR-peptide resulted in a reduction of fluorochrome concentration in HT-1080 tumor tissue (195.3±21.9 nM; 5 h). We thus conclude that NGR-Cy 5.5 combined with novel tomographic optical imaging methods allows us to image and quantify tumor-associated CD13/APN expression noninvasively. This may be a promising strategy for a sensitive evaluation of tumor angiogenesis in vivo.